- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03974958
Circulating microRNAs and Degenerative Abdominal Aorta Aneurysm (ACTA-miRNA)
Circulating microRNAs and Degenerative Abdominal Aorta Aneurysm: Diagnostic Specificity and Prognostic Value in Clinical Practice
Abdominal aortic aneurysm (AAA) is an aortic dilatation superior or equal to 30 mm with an estimated prevalence at 8% in men over 65 year-old. It evolves with no clinical signal until the rupture of the aortic wall with dramatic outcomes. The pathophysiological mechanisms include extracellular matrix remodeling, smooth muscle cells apoptosis, aggregation and activation of inflammatory cells in the aortic wall and heredity. The initiating and regulatory processes are complex and not fully elucidated. They encompass local aortic environment (flux, thrombus, wall shear stress, pressure and adipose tissue) and patient-dependent genetic (de)regulation.
This project follows the previous prospective ACTA study that aimed at identifying clinical criteria, circulating biomarkers or imaging data for thoracic aneurysm prognosis in an AAA population. The preliminary results showed that 1) a low wall shear stress index and the luminal volume are more predictive values for a rapid AAA growth and an intraluminal thrombus than the maximal aortic diameter 2) three thoracic aortic phenotypes (normal, dilated, aneurysmal) stratify the disease extent 3) the age and the female gender are associated to an extended disease. During this study we created a biobank in which blood samples of AAA patients were collected at the time of their inclusion (T1). This new ACTA-miRNA study aims at correlating circulating biomarkers to the anatomical and biomechanical markers previously highlighted for a rapid aneurysmal growth. Circulating miRNA are involved in parietal remodeling and constitute promising targets for estimating patients-specific aortic risk.
From the literature, we thus selected 18 miRNA described to be involved in AAA biology: inflammation, remodeling, cellular homeostasis and wall shear stress. As control, we select non-AAA patients presenting with peripheral arterial obstructive disease (PAOD) matched in age, BMI, tobacco consumption, diabetes, cholesterol level and blood pressure with AAA patients enrolled in the ACTA study. During their follow-up, these ACTA patients are solicited to continue the program research and can participate to the ACTA-miRNA study. A third time analysis is performed for them (T3): we collect imaging data of total aorta required by their standard follow-up, as well as a blood sample. Differential analysis of the miRNA panel will be conducted between 1) AAA patients (T1) vs PAOD patients 2) fast-growing AAA vs slow-growing AAA 3) AAA & AAT patient group vs AAA alone and/or AAA & dilatation of thoracic aorta. 110 patients from the ACTA study are eligible to be included into the ACTA mi-RNA study. Inclusion of PAOD controls will be conducted until the number of 165 cases is reached (1:1.5 ratio).
Our primary objective is to validate a circulating-miRNA signature specific for abdominal aortic aneurysm.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Laurence Bal, MD
- Email: laurence.bal@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13005
- Assistance Publique Hopitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
• Case AAA T3 : Patients included in the ACTA study. They benefited from aortic imaging assessment at times T1 and T2 and were not operated on AAA.
• AOMI Case Control : Patients referred for hospitalization or referred to vascular surgery for management of chronic peripheral claudication on AOMI not associated with aneuric aneurysm evolutionary or previously operated. They must benefit from a CT angiography of the aorta and lower extremity arteries as well as a cardiac ultrasound scan.
Exclusion Criteria:
- minor patients;
- pregnant women;
- patients with cancer at the time of inclusion;
- contraindication to iodinated contrast medium: allergy to iodine, severe renal insufficiency (≤40 ml / min);
patients presenting one of the following pathologies associated with a disruption of the activation of coagulation and / or inflammation (less than 6 weeks old):
- Arterial thrombotic disease: acute coronary syndrome, TIA/CVD, peripheral artery acute ischemia and/or anti-vitamin K (AVK) treatment;
- venous thrombotic pathology: peripheral venous thrombosis of less than 3 months and/or under AVK treatment, pulmonary embolism less than 6 months old and/or under AVK treatment;
- surgery;
- revascularization with angioplasty;
- critical ischemia patente;
- permanent atrial fibrillation due to associated microparticle elevation, and AVK treatment;
- major haemorrhage;
- acute infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AAA patients
Patients with abdominal aortic aneurysm (AAA)
|
circulating biomarkers (miRNA panel) analysis of blood samples
|
Experimental: PAOD patients
patients with peripheral arterial obstructive disease (PAOD)
|
circulating biomarkers (miRNA panel) analysis of blood samples
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of AAA miRNAs vs AOMI miRNAs
Time Frame: 24 months
|
Analyze the diagnostic value of the 18 selected microRNAs circulating profile in degenerative aneurysmal aortic remodeling (patients with an abdominal aortic aneurysm (AAA)) in comparison with the circulating profile of the same 18 microRNAs panel in the atherosclerosis remodeling (patients with peripheral arterial occlusive disease (AOMI) without AAA)
|
24 months
|
Collaborators and Investigators
Investigators
- Study Director: Emilie Garrido Pradalié, Assistance Publique Hopitaux de Marseille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-12
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abdominal Aorta Aneurysm
-
Maquet CardiovascularCompletedAbdominal Aorta AneurysmFrance, Germany
-
Central Hospital, Nancy, FranceCompletedMedically-treated Aneurysm of Abdominal AortaFrance
-
University of LiegeKU LeuvenCompletedPeriodontitis | Dentulous | Abdominal Aorta Aneurism
-
Łukasz KrzychCompletedPain, Postoperative | Surgery | Abdominal Aorta Aneurysm | Abdominal Aorta AtheromaPoland
-
Petrovsky National Research Centre of SurgeryRecruitingAorta Abdominalis; Aneurysm | Aorta Thoracic; AneurysmRussian Federation
-
University of North Carolina, Chapel HillCook Group Incorporated; UNC HospitalsEnrolling by invitationAortic Aneurysm, Abdominal | Aortic Arch Aneurysm | Ascending Aorta AneurysmUnited States
-
Centre Hospitalier Universitaire DijonWithdrawnAneurysm of the Abdominal Aorta
-
Nectero Medical, Inc.Active, not recruitingAbdominal Aortic Aneurysm | AAA | Dilation AortaNew Zealand, Australia, China, Colombia
-
Endovascular FoundationW.L.Gore & Associates; Bocconi UniversityRecruitingThoracic Aorta | Thoracic Aorta Aneurysm | Thoracic Aorta AbnormalitySpain, Italy
-
Gangnam Severance HospitalCompletedDissecting Aneurysm of the Thoracic Aorta | Chronic Dissecting Aneurysm of Thoracic Aorta | Chronic Nontraumatic Dissection of Thoracic AortaKorea, Republic of
Clinical Trials on Tissue-library
-
Yale UniversityNational Library of Medicine (NLM)Not yet recruitingPersonal Health Information | Incarcerated IndividualsUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
dfusion IncActive, not recruiting
-
Royal Marsden NHS Foundation TrustRecruitingBreast Cancer FemaleUnited Kingdom
-
University of MinnesotaRecruitingAnesthesia | Anesthesia Intubation ComplicationUnited States
-
China National Center for Cardiovascular DiseasesUnknownCoronary Heart Disease | Diastolic DysfunctionChina
-
Université de MontréalUnknownUsing Expert Visual Search Strategy to Train Students to Read the Chest X-rayCanada
-
Dartmouth-Hitchcock Medical CenterNational Cancer Institute (NCI)CompletedHepatocellular CarcinomaUnited States
-
University of Sao PauloHarvard Medical School (HMS and HSDM); University of Copenhagen; Fundação de... and other collaboratorsCompletedCognition Disorders | Impaired Cognition | Self-AssessmentBrazil
-
Yale UniversityAlzheimer's Therapeutic Research InstituteCompletedAlzheimer's DiseaseUnited States, Canada